Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (ADVANCE-II)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03697707 |
Recruitment Status :
Active, not recruiting
First Posted : October 5, 2018
Last Update Posted : October 10, 2022
|
Sponsor:
Mendus
Collaborator:
Amsterdam UMC, location VUmc
Information provided by (Responsible Party):
Mendus
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | October 4, 2018 | ||||
First Posted Date ICMJE | October 5, 2018 | ||||
Last Update Posted Date | October 10, 2022 | ||||
Actual Study Start Date ICMJE | October 15, 2018 | ||||
Estimated Primary Completion Date | March 2023 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
minimal residual disease (MRD) [ Time Frame: up to 32 weeks ] Any change in MRD (flow cytometric) as compared to baseline MRD
|
||||
Original Primary Outcome Measures ICMJE |
|
||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia | ||||
Official Title ICMJE | An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD | ||||
Brief Summary | Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD | ||||
Detailed Description | International, multicentre, open-label proof of concept study exploring two different dose groups of the allogeneic dendritic cell vaccine, DCP-001. Cohort 1 consists of 10 patients that will receive 25E6 DCP-001 cells per vaccination and Cohort 2 consists of 10 patients who will receive 50E6 DCP-001 cells per vaccination. All patients will be given two additional booster vaccinations of 10E6 cells. Each patient will be followed up for 12 months after the 4th vaccination. Safety will be monitored throughout the study. Sera and cell samples (blood and bone marrow) will be collected for assessment of efficacy (MRD evaluation) and immune response monitoring. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Sequential Assignment Intervention Model Description: First 10 patients will get the lowest dose and next 10 patients will receive the highest dose Masking: None (Open Label)Primary Purpose: Treatment |
||||
Condition ICMJE | Acute Myeloid Leukemia in Remission | ||||
Intervention ICMJE | Biological: DCP-001
allogeneic dendritic cell vaccine
|
||||
Study Arms ICMJE |
|
||||
Publications * | van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Estimated Enrollment ICMJE |
20 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | December 2025 | ||||
Estimated Primary Completion Date | March 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Finland, Germany, Netherlands, Norway, Sweden | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03697707 | ||||
Other Study ID Numbers ICMJE | DCOne-002 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Current Responsible Party | Mendus | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Mendus | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Amsterdam UMC, location VUmc | ||||
Investigators ICMJE |
|
||||
PRS Account | Mendus | ||||
Verification Date | October 2022 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |